Beta-3 adrenoceptor agonists for the treatment of pulmonary hypertension
The invention relates to the use of selective agonists of beta-3 adrenergic receptors for the treatment and/or prevention of pulmonary hypertension.
1. A method for treating pulmonary hypertension due to left heart disease (group 2 PH) in a subject in need thereof, the method comprising administering to said subject an effective amount of a selective beta-3 adrenergic receptor agonist compound or a pharmaceutically acceptable salt thereof, wherein said selective beta-3-adrenergic receptor agonist compound is selected from the group consisting of YM178 (Mirabegron) and BRL 37344, such that said group 2 PH in said subject is treated.
2. The method of claim 1 , wherein the pulmonary hypertension comprises acute pulmonary thromboembolism.
3. A method of treating pulmonary hypertension due to left heart disease (group 2 PH) in a subject in need thereof, the method comprising administering to said subject an effective amount of YM178 (Mirabegron) or a pharmaceutically acceptable salt thereof, such that said group 2 PH in said subject is treated.
4. The method of claim 1 , wherein said selective beta-3-adrenergic receptor agonist compound is YM178 (Mirabegron).
5. The method of claim 1 , wherein said selective beta-3-adrenergic receptor agonist compound is BRL 37344.
6. The method of claim 1 , wherein the subject is a human.
7. The method of claim 1 , wherein the subject does not experience significant side effects on systemic circulation.
8. The method of claim 7 , wherein the subject does not experience significant changes in systemic blood pressure.
9. The method of claim 7 , wherein the subject does not experience significant changes in heart rate.